ACRS relative valueRV
Aclaris Therapeutics, Inc.. How this company compares with the rest of its GICS sub-industry on the figures it reported in its last annual filing.
ACRS's operating margin of -975.9% ranks in the 14th percentile of 17 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
As of . Source: SEC EDGAR XBRL company facts. Method and limitations.
Against 24 Pharmaceuticals peers
| Metric | ACRS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 7.8M USD | 411M USD | 8th | 19 |
| Revenue YoY | n/a | n/a | n/a | n/a |
| Gross margin | n/a | 56.3% | n/a | 6 |
| Operating margin | -975.9% | 12.6% | 14th | 17 |
| Net margin | -829.6% | 1.2% | 13th | 18 |
| Return on equity | -63.0% | -3.6% | 16th | 21 |
| P / E | n/a | 13.9x | n/a | 10 |
| 1 year | n/a | n/a | n/a | n/a |
Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal periods ending between 2025-12-31 and 2026-06-30. Prices as of 2026-09-18. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001104659-26-020540
Peer set, 24 companies
ESPR, COLL, PCRX, AMPH, ALMS, ANRO, OMER, PAHC, XERS, INVA, AVIR, ANIP, BIOA, NUVB, TRVI, FULC, BHC, NKTR, OCUL, SUPN, HRMY, GPCR, SIGA, OGN
Left out: ACB (period gap).
What could not be compared
- 60 The filer did not report this line in the filing used.
- 24 The price series does not reach back to the start of this window.
- 19 The denominator is zero or negative, so the ratio has no meaning.
- 2 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
- 2 The newest price is more than 10 days old.
- 1 This company's fiscal year ends more than 200 days from the subject's, so it is a different economic year.
Free account
Open the relative value desk with a free account
An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, the filing behind every cell, and CSV. The table above stays free.
Cite this data
Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's GICS sub-industry. A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.
Upstream: SEC EDGAR XBRL company facts
Kresmion, "ACRS relative value, Kresmion", data as of 2026-02-26, https://kresmion.com/tools/relative-value/ACRS. Upstream data: SEC EDGAR XBRL company facts.